CY1115178T1 - Βιοδεικτες καρκινου - Google Patents

Βιοδεικτες καρκινου

Info

Publication number
CY1115178T1
CY1115178T1 CY20141100091T CY141100091T CY1115178T1 CY 1115178 T1 CY1115178 T1 CY 1115178T1 CY 20141100091 T CY20141100091 T CY 20141100091T CY 141100091 T CY141100091 T CY 141100091T CY 1115178 T1 CY1115178 T1 CY 1115178T1
Authority
CY
Cyprus
Prior art keywords
cancer
biomarker
industries
detection
peptide
Prior art date
Application number
CY20141100091T
Other languages
Greek (el)
English (en)
Inventor
Hardev Pandha
Richard George Leonard Morgan
Original Assignee
The University Of Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Surrey filed Critical The University Of Surrey
Publication of CY1115178T1 publication Critical patent/CY1115178T1/el

Links

Classifications

    • G01N33/57555
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CY20141100091T 2006-12-19 2014-02-05 Βιοδεικτες καρκινου CY1115178T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
EP07848631.3A EP2115472B1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (1)

Publication Number Publication Date
CY1115178T1 true CY1115178T1 (el) 2016-12-14

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100091T CY1115178T1 (el) 2006-12-19 2014-02-05 Βιοδεικτες καρκινου

Country Status (19)

Country Link
US (1) US8460882B2 (enExample)
EP (1) EP2115472B1 (enExample)
JP (1) JP5683108B2 (enExample)
CN (1) CN101675341B (enExample)
AU (1) AU2007335999B2 (enExample)
BR (1) BRPI0720371B8 (enExample)
CA (1) CA2671939C (enExample)
CY (1) CY1115178T1 (enExample)
DK (1) DK2115472T3 (enExample)
ES (1) ES2445185T3 (enExample)
GB (2) GB0625321D0 (enExample)
IL (1) IL199241A (enExample)
MX (1) MX2009006378A (enExample)
NZ (1) NZ577548A (enExample)
PL (1) PL2115472T3 (enExample)
PT (1) PT2115472E (enExample)
RU (1) RU2460075C2 (enExample)
SI (1) SI2115472T1 (enExample)
WO (1) WO2008075056A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
JP2012532621A (ja) * 2009-07-13 2012-12-20 ザ ユニバーシティ オブ サリー 治療ペプチド、ポリペプチド及び核酸配列
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2013037118A1 (zh) * 2011-09-16 2013-03-21 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
US20140336130A1 (en) * 2011-12-05 2014-11-13 Phigenix, Inc. Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
WO2014005138A1 (en) * 2012-06-29 2014-01-03 Kerschensteiner Daniel A Colorimetric gelatinase assay
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
EP2994753B1 (en) * 2013-05-09 2018-03-07 The Procter and Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP3303616B1 (en) * 2015-05-29 2021-01-06 Koninklijke Philips N.V. Methods of prostate cancer prognosis
EP3960195B1 (en) * 2015-09-23 2025-01-08 Centre national de la recherche scientifique Engrailed for treatment of amyotrophic lateral sclerosis
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
EP3564365B1 (en) * 2016-12-28 2023-01-25 Guangzhou Institutes Of Biomedicine And Health Chinese Academy Of Sciences Transdifferentation of b lymphoid cells into t cells
KR101777085B1 (ko) * 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777254B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295303A1 (en) * 1997-06-27 1999-01-07 Human Genome Sciences Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
JP2002527758A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
WO2001092879A1 (en) 2000-05-30 2001-12-06 Danmarks Miljø Undersøgelser An assay method and kit for testing biological material for exposure to stress using biomarkers
EP1297182A2 (en) * 2000-06-30 2003-04-02 Epigenomics AG Diagnosis of diseases associated with cell signalling
US20050079492A1 (en) * 2000-09-12 2005-04-14 Burgess Jr. Robert M. Micro-arrayed organization of transcription factor target genes
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
WO2002054936A2 (en) 2000-12-24 2002-07-18 Kohn, Kenneth, I. A method for detecting biomarkers
WO2002070742A1 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
EP1831399B1 (en) * 2004-12-02 2009-08-05 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
WO2006089091A2 (en) * 2005-02-18 2006-08-24 Memorial Sloan-Kettering Cancer Center Methods for detecting minimum residual disease

Also Published As

Publication number Publication date
BRPI0720371A2 (pt) 2013-12-31
WO2008075056A1 (en) 2008-06-26
AU2007335999B2 (en) 2013-09-05
JP5683108B2 (ja) 2015-03-11
EP2115472A1 (en) 2009-11-11
IL199241A (en) 2014-03-31
AU2007335999A1 (en) 2008-06-26
US8460882B2 (en) 2013-06-11
GB0625321D0 (en) 2007-01-24
PL2115472T3 (pl) 2014-05-30
MX2009006378A (es) 2009-08-24
BRPI0720371B1 (pt) 2019-05-28
CN101675341A (zh) 2010-03-17
SI2115472T1 (sl) 2014-05-30
JP2010513901A (ja) 2010-04-30
EP2115472B1 (en) 2013-11-06
DK2115472T3 (da) 2014-02-10
ES2445185T3 (es) 2014-02-28
PT2115472E (pt) 2014-02-14
BRPI0720371B8 (pt) 2021-07-27
GB0719792D0 (en) 2007-11-21
CN101675341B (zh) 2017-08-08
US20100093558A1 (en) 2010-04-15
RU2460075C2 (ru) 2012-08-27
RU2009127774A (ru) 2011-01-27
CA2671939A1 (en) 2008-06-26
NZ577548A (en) 2012-03-30
CA2671939C (en) 2017-10-03

Similar Documents

Publication Publication Date Title
CY1115178T1 (el) Βιοδεικτες καρκινου
CY1119956T1 (el) Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου
CY1121899T1 (el) Βοριουχα μικρομορια ως αντιφλεγμονωδεις παραγοντες
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
CY1111676T1 (el) Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη
CY1120434T1 (el) Πρωτεϊνες προσδεσης il-1
MX2018005087A (es) Mutaciones puntuales en cáncer resistente a trk y métodos relacionados con las mismas.
IL285310A (en) Detecting cancer, cancer tissue of origin, and/or a cancer cell typ
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
WO2008128169A8 (en) Sparc and methods of use thereof
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
CY1120208T1 (el) Νεροτσουληθρα
MX2017015461A (es) Métodos para diagnosticar y tratar el cáncer.
CR11504A (es) Deteccion mejorada de la expresion de mage-a
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
NO20084546L (no) Diagnostikk og behandlinger for tumorer
BR112014032728A2 (pt) uso de marcadores no diagnóstico e tratamento de câncer de próstata
CY1118933T1 (el) Anti-cxcr1 συνθεσεις και μεθοδοι
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
BRPI0809137A2 (pt) métodos de diagnosticar, câncer endometrial e pré-câncer classificar e tratar
ECSP099523A (es) Antagonistas específicos de VEGF para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadíos tempranos
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
DK2024747T3 (da) Anvendelse af protein SATB2 som prognotisk markør for colerectal cancer
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer